Head to Head Survey: Anixa Biosciences (NASDAQ:ANIX) & Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio (NASDAQ:TVGN) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Profitability

This table compares Tevogen Bio and Anixa Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Anixa Biosciences	N/A	-71.12%	-62.88%

Analyst Ratings

This is a summary of current ratings and recommmendations for Tevogen Bio and Anixa Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1	1	0	0	1.50
Anixa Biosciences	1	1	3	0	2.40

Tevogen Bio presently has a consensus target price of $100.00, suggesting a potential upside of 1,351.38%. Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 144.25%. Given Tevogen Bio’s higher probable upside, equities research analysts plainly believe Tevogen Bio is more favorable than Anixa Biosciences.

Institutional & Insider Ownership

29.1% of Anixa Biosciences shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Tevogen Bio has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Earnings and Valuation

This table compares Tevogen Bio and Anixa Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27 million	($4.63)	-1.49
Anixa Biosciences	$210,000.00	563.76	-$10.93 million	($0.31)	-11.23

Anixa Biosciences has higher revenue and earnings than Tevogen Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Anixa Biosciences beats Tevogen Bio on 8 of the 12 factors compared between the two stocks.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.